Scandium-47 [T½ = 3.35 d, Eβ-(max.) = 600 keV, Eγ = 159 keV] is a relatively new radioisotope that holds tremendous potential for use in cancer theranostics. The radioisotope was produced by thermal neutron irradiation of enriched 46Ca producing 47Ca, which decays by β− emission to 47Sc. A viable method based on the selective electroamalgamation of Ca2+ ions has been developed for the clinical-scale separation of 47Sc from 47Ca. The overall yield of 47Sc after the separation process was >80% and it was obtained with >99.9% radionuclidic purity in a form suitable for radiopharmaceutical preparation. This strategy holds promise for future clinical translation of this radioisotope.
No takes yet. Share an insight, caveat, or question.
Chakravarty et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: